Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00427609 · ClinicalTrials.gov registry record · Phase 2
Bicillin L-A vs Placebo for the Treatment of Chronic, Plaque-Type Psoriasis Unresponsive to Topical Medications
A Phase 2 study, sponsored by University of Tennessee.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT00427609 is a Phase 2 study that was terminated before completion, run by University of Tennessee. The registered enrollment target is 5 participants.
The verdict
NCT00427609, a Phase 2 study, was terminated before completion, sponsored by University of Tennessee.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy for Bicillin L-A, administered intramuscularly in a dose of 2.4 million units every three (3) weeks, for the treatment of chronic, plaque-type psoriasis unresponsive to topical medications or when other systemic therapies are contraindicated.
Interventions
- DRUG Bicillin L-A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2007-01 |
| Est. Completion | 2009-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00427609
The ClinicalTrials.gov registry entry for NCT00427609 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Tennessee, which has 96 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bicillin L-A is the first listed.
NCT00427609 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00427609 about?
NCT00427609 is a clinical study titled "Bicillin L-A vs Placebo for the Treatment of Chronic, Plaque-Type Psoriasis Unresponsive to Topical Medications". The purpose of this study is to determine the efficacy for Bicillin L-A, administered intramuscularly in a dose of 2.4 million units every three (3) weeks, for the treatment of chronic, plaque-type psoriasis unresponsive to topical medications or when other systemic therapies are contraindicated.
What is the current status of trial NCT00427609?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2007-01. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00427609?
The interventions under investigation include: Bicillin L-A (DRUG).
Who is sponsoring clinical trial NCT00427609?
This trial is sponsored by University of Tennessee, which has 96 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.